FX-909   Click here for help

GtoPdb Ligand ID: 12626

Synonyms: FX 909 | FX909
Compound class: Synthetic organic
Comment: FX-909 is a first-in-class oral, covalent inverse agonist of the peroxisome proliferator activated receptor gamma (PPARG) nuclear hormone receptor [1]. It was developed for anti-tumour potential. The chemical structure was disclosed during the 'First Disclosures of New Drug Candidates' session at the April 2023 (Orlando) meeting of the AACR.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 95.41
Molecular weight 360.34
XLogP 0.84
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CS(=O)(=O)C1=C(C=C(C=C1)C#N)C2=CC(=O)C3=C(C=C(C=C3F)F)N2
Isomeric SMILES CS(=O)(=O)C1=CC=C(C=C1C2=CC(=O)C3=C(N2)C=C(F)C=C3F)C#N
InChI InChI=1S/C17H10F2N2O3S/c1-25(23,24)16-3-2-9(8-20)4-11(16)13-7-15(22)17-12(19)5-10(18)6-14(17)21-13/h2-7H,1H3,(H,21,22)
InChI Key RBUBBZVQPHSZEZ-UHFFFAOYSA-N
References
1. Sims R, Mertz JA, Wilson JE, Audia JE, Williamson KE, Li Y, Kuljanin M, Motely WW, DeLaBarre B,Bowden M et al.. (2023)
Abstract ND08: Discovery of FX-909, a first-in-class inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor, to potentially treat patients with the luminal subtype of advanced urothelial cancer (UC).
Cancer Research, 83 (7_Supplement). DOI: 10.1158/1538-7445.AM2023-ND08